wjpmr, 2024, 10(8), 58-64

SJIF Impact Factor: 6.842

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Review Article

ISSN 2455-3301

WJPMR

THE EFFICACY AND SAFETY OF BIOLOGIC THERAPIES IN THE TREATMENT OF PSORIASIS: A COMPREHENSIVE REVIEW

Kartik G. Jadhav[1*], Shaikh Sameer Shaikh Farid[2], Syed Nabeel Ahmad[3], Rathod Ashwin Datta[4] and Syed Saqlain Syed Saleem[5]

[1,5]Pharm.D, Swami Ramanand Teerth Marathwada University, Nanded.

***Corresponding Author: Kartik G. Jadhav**

Pharm.D, Swami Ramanand Teerth Marathwada University, Nanded.

Email ID: kartikjadhao85.kj@gmail.com

Article Received on 31/05/2024 **Article Revised on 21/06/2024** **Article Accepted on 11/07/2024**

ABSTRACT

Millions of people worldwide suffer with psoriasis, a chronic inflammatory skin illness caused by the immune system that is typified by erythematous plaques covered in silvery scales. Targeting certain cytokines and immunological pathways, biologic medicines have become essential in the management of moderate to severe psoriasis, despite the availability of many other therapy alternatives. This thorough analysis summarizes the state of knowledge about the pathogenesis of psoriasis, conventional treatments, and the development of biologic medicines. The mechanisms of action, clinical effectiveness, and safety profiles of important biologic medicines, such as PDE4 inhibitors, IL-17 and IL-23 inhibitors, TNF-alpha inhibitors, and IL-12/23 inhibitors, are covered. Comparative efficacy, long-term safety concerns, patient outcomes, and potential avenues for future biologic treatment research are highlighted. The purpose of this review is to give researchers and physicians a thorough understanding to enhance treatment approaches and enhance psoriasis management results.

KEYWORDS: Psoriasis, biologic therapies, TNF-alpha inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors, PDE4 inhibitors, efficacy, safety.

INTRODUTION

Skin cells accumulate quickly in psoriasis, a chronic inflammatory disease. The accumulation causes scaling on the skin's surface, which is frequently accompanied by itching, redness, and inflammation. Though it may arise anywhere on the body, it usually affects the skin of the elbows, knees, scalp, and lower back. Although psoriasis is not communicable, its severity can range from moderate, causing little areas of dry skin, to severe, resulting in thick, crusty plaques covering the skin.[1,2]

According to the epidemiology of psoriasis in India, between 0.44% and 2.8% of people are estimated to be affected. These numbers may differ depending on the various demographics and geographic areas of the nation. In comparison to rural regions, metropolitan areas tend to have a higher frequency. Although psoriasis can afflict people of any age, it often manifests itself between the ages of 15 and 30 and 50 and 60.

There are several forms of psoriasis, and each has unique characteristics.

1. **Plaque Psoriasis (Psoriasis Vulgaris):** Psoriasis vulgaris, or plaque psoriasis, is the most prevalent kind and is typified by elevated, red areas that are coated in a silvery white accumulation of dead skin cells, or scales. While these patches can develop anywhere on the body, they frequently do so on the lower back, scalp, elbows, and knees.
2. **Guttate Psoriasis:** This skin condition, which is frequently brought on by bacterial infections such as strep throat, manifests as tiny, drop-shaped lesions on the scalp, arms, legs, and trunk. It affects children and young adults more frequently.
3. **Inverse Psoriasis:** This kind usually affects skin folds like those beneath the breasts, in the groin, or around the genitalia and buttocks. It manifests as smooth, red patches of irritated skin. Sweating and friction make it worse.
4. **Pustular Psoriasis:** This rare kind results in red skin around pus-filled blisters, called pustules. It might be localized, affecting only certain parts of the body like the hands and feet, or widespread.
5. **Erythrodermic Psoriasis:** The rarest and most severe kind, erythrodermic psoriasis can cause a red, peeling rash that can burn or itch severely across the entire body. It can result in serious sickness and need emergency care.
6. **Psoriatic Arthritis:** Psoriatic arthritis is a kind of arthritis that occurs in certain psoriasis sufferers. In extreme situations, this disorder may result in joint

deterioration along with pain, stiffness, and swelling in the joints.[3,4,5]

ETIOPATHOGENISIS

Psoriasis is a long-term autoimmune skin condition that causes skin cells to accumulate quickly, causing redness, irritation, and scaling on the skin's surface. Environmental variables, genetic predisposition, and immunological dysfunction interact intricately in the etiology of psoriasis. This is a thorough explanation of its pathophysiology.

1. **Genetic Predisposition**
   - Psoriasis has a significant hereditary basis. Susceptibility is influenced by variations in a number of genes, including those related to the immune system and the function of the skin barrier. Variations in the HLA-C gene, in particular the HLA-C*06:02 variant, which is linked to an increased risk of psoriasis, are the most important genetic risk factor.
2. **Immune Dysregulation**
   - **T Cells Activation:** T cells, particularly CD4+ and CD8+ T cells, are activated in the skin lesions of psoriasis. Tumor necrosis factor-alpha (TNF-alpha), interleukin-17 (IL-17), and interleukin-22 (IL-22) are among the cytokines released by these T cells.
   - **Cytokine Release:** IL-17 and IL-22 cause inflammation and encourage the growth of keratinocytes, or skin cells. Additionally, TNF-alpha is essential for the inflammation and tissue damage associated with psoriasis.
   - **Dendritic Cells:** Skin-resident antigen-presenting dendritic cells expose T lymphocytes to self-antigens, inducing an immunological reaction directed against healthy skin cells.
3. **Keratinocyte Hyperproliferation**
   - The main characteristic of psoriasis is the hyperproliferation of Keratinocytes, which causes the skin to shed rapidly (usually every 3–4 days as opposed to 28–30 days in normal skin). Cytokines such as TNF-alpha and IL-17 stimulate aberrant communication between immune cells and keratinocytes, which impairs normal skin cell development and turnover.
4. **Inflammatory Cascade**
   - Chemokines, such as CCL20, draw immune cells to the skin lesions, causing the inflammation to persist. Psoriatic lesions also show enhanced angiogenesis, or the growth of new blood vessels, which fuels the metabolic needs of keratinocytes that divide quickly and prolongs inflammation.
5. **Environmental Triggers**
   - In people who are genetically predisposed to psoriasis, conditions including infections (such as streptococcal throat infections), skin trauma (Koebner phenomenon), stress, and some drugs (such lithium and beta-blockers) can cause or worsen psoriasis.
6. **Chronic Inflammation and Skin Damage**
   - Acanthosis, hyperkeratosis, and the development of recognizable plaques are skin damage outcomes of the psoriasis's ongoing inflammatory condition. Prolonged inflammation can also raise the risk of comorbid conditions like cardiovascular disease and contribute to systemic inflammation over time.

Comprehending these pathways facilitates the development of focused treatments intended to regulate the immune system or obstruct certain cytokines implicated in the pathogenesis of psoriasis. The intricacy of psoriasis emphasizes the necessity of individualized treatment plans designed for each patient.[6,7,8,9]

MANAGEMENT

A comprehensive strategy is needed to manage psoriasis with the goals of minimizing symptoms, averting flare-ups, and enhancing quality of life. Plans for treatment are customized according to the kind and degree of psoriasis as well as personal preferences, age, and general health.

1. Topical Treatments

- **Corticosteroids:** These are anti-inflammatory drugs that help lessen skin cell turnover, irritation, and itching. Depending on the area and severity of psoriasis, they come in different formulations (ointments, creams, and gels) and strengths.
- **Topical Retinoids:** Made from vitamin A, retinoids aid in lowering inflammation and restoring a normal rate of skin cell turnover.
- **Calcineurin Inhibitors:** Topical immunomodulators such as tacrolimus and pimecrolimus reduce inflammation and are beneficial for sensitive regions such as the face and folds of skin.
- **Coal Tar Preparations:** For many years, psoriasis has been treated with them. They aid in lowering inflammation, scaling, and itching.

2. Phototherapy (Light Therapy)

- **UVB Phototherapy:** This includes exposing the skin to UVB light, which lowers inflammation and slows down the skin cells' fast proliferation. It can be carried out under medical supervision at home or at a doctor's office.
- **PUVA Therapy:** For more severe instances of psoriasis, psoralen in combination with UVA light treatment (PUVA) is an additional alternative. A photosensitizing drug called prisoralen increases the skin's sensitivity to UVA rays.

3. Systemic Medications

- **Biologic Therapies:** These more recent drugs concentrate on particular immune system components linked to psoriasis. Biologics include TNF-alpha inhibitors (etanercept, adalimumab), IL-17 inhibitors (secukinumab, ixekizumab), and IL-23 inhibitors (ustekinumab), which are often given by injection or infusion.

- **Conventional Systemic Agents:** These comprise oral drugs such acitretin, methotrexate, and cyclosporine. They function to lower skin cell turnover or inhibit the immune system.

4. Combination Therapies

- **Sequential Therapy:** Using a step-by-step method to combine various medicines might occasionally increase efficacy and lessen negative effects.
- **Topical + Phototherapy:** When combined with light therapy, topical therapies can improve outcomes, especially for localized psoriasis.

5. Lifestyle Modifications

- **Avoid Triggers:** Recognizing and steering clear of triggers including infections, stress, skin injuries, and certain drugs can help avert flare-ups.
- **Moisturizers:** Using moisturizers on a regular basis keeps the skin nourished and may lessen scaling and irritation.
- **Healthy Lifestyle:** Reducing alcohol intake, quitting smoking, and keeping a healthy weight can all help lessen the severity of psoriasis.

6. Patient Education and Support

- **Education:** Having a thorough understanding of psoriasis, its causes, and available treatments helps people take charge of their health.
- **Support Groups:** Attending therapy or joining support groups can offer psychological assistance as well as useful advice for managing psoriasis.

7. Regular Follow-Up

- **Monitoring:** To control side effects, track the efficacy of treatments, and make any adjustments to treatment regimens, routine visits to healthcare specialists are required.[10,11,12,13]

BIOLOGIC THERAPIES

A class of medical interventions known as biologic therapy aims to address certain molecules that have a role in the inflammatory process. They are commonly used to treat autoimmune conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease (IBD). Biologics are more focused than conventional drugs, which often inhibit the immune system by blocking certain proteins that cause inflammation, such as integrins, interleukins, and tumor necrosis factor-alpha.

These treatments, which are often given by injection or infusion, are frequently recommended in place of more potent ones or in cases where the negative effects of corticosteroids or immunosuppressants have become unacceptable. For many patients suffering from chronic inflammatory disorders, biologics can help lower inflammation, manage symptoms, and even bring about remission. However, their usage need close supervision by healthcare professionals because they may potentially raise the risk of infections and have other possible adverse effects.[14,15]

SIGNIFICANCE OF BIOLOGIC THERAPY IN PSORIASIS TREATMENT

By precisely targeting immune system proteins that are essential to the development of psoriasis, biologic treatments have completely changed the way the disease is treated

1. **Targeted Approach**: TNF-alpha, interleukins (IL-12, IL-23, and IL-17), T cells, and other molecules implicated in the inflammatory process are among the molecules that biologics target in order to function. Biologics can lessen the excessive inflammation that causes psoriatic symptoms by inhibiting these targets.
2. **Efficacy**: In many people, they are quite effective, leading to a quick and noticeable reduction in skin lesions and joint problems in psoriatic arthritis sufferers.
3. **Long-term Management**: The quality of life can be enhanced and psoriasis symptoms can be kept under control with the use of biologics. Several biologics have demonstrated long-term efficacy during years of therapy.
4. **Administration**: Injections or infusions are the usual ways in which they are given. The particular biologic and the patient's reaction determine how frequently a treatment is administered
5. **Safety Profile**: Although biologics are usually well tolerated, they can cause side effects such as an elevated risk of infections and, in certain situations, uncommon but severe adverse events. Healthcare professionals' routine observation helps to reduce these hazards.
6. **Patient Selection**: Patients with moderate to severe psoriasis who have not reacted well to topical medicines, phototherapy, or systemic drugs such as cyclosporine or methotrexate are frequently candidates for biologics.
7. **Significance**: Patients who previously had few effective treatment choices for psoriasis now have more alternatives because to the development of biologic medicines. They are a significant development in the treatment of this inflammatory chronic illness.

Overall, by offering focused and efficient symptom management, biologic medicines have greatly improved outcomes for a large number of psoriasis patients. Nevertheless, their administration necessitates careful consideration of unique patient variables and continuous monitoring.[16,17]

TYPES OF BIOLOGIC THERAPIES

Psoriasis is treated using biologic medicines that specifically target immune response molecules, especially cytokines, which are important in the disease's inflammatory processes. The many kinds of biologic medicines that are frequently employed to treat psoriasis

are listed below, along with their mechanisms and outcome.

1. **TNF-alpha Inhibitors**
   - **Mechanism:** A pro-inflammatory cytokine that is essential to the inflammatory process of psoriasis is tumor necrosis factor-alpha, or TNF-alpha. TNF-alpha medications reduce inflammation by inhibiting TNF-alpha's activity.
   - **Examples:** Etanercept, Adalimumab, Infliximab
   - **Effect:** Psoriatic arthritis symptoms, such as skin lesions and joint involvement, recover quickly. efficient for moderate-to-severe psoriasis that is unresponsive to conventional therapies.

2. **IL-17 Inhibitors**
   - **Mechanism:** A cytokine called interleukin-17 (IL-17) promotes inflammation and keratinocyte proliferation, which is part of the pathophysiology of psoriasis. IL-17 inhibitors prevent the production of IL-17A, a particular isoform linked to psoriasis.
   - **Examples:** Secukinumab, Ixekizumab, Brodalumab
   - **Effect:** Psoriatic plaques and symptoms are reduced quickly and significantly, frequently with long-lasting results. potent for psoriasis ranging from mild to severe.

3. **IL-23 Inhibitors**
   - **Mechanism:** The production of IL-17 and other pro-inflammatory cytokines by T helper 17 (Th17) cells is dependent on the differentiation and activation of interleukin-23 (IL-23). Inhibitors of IL-23 suppress the p19 component of IL-23, which lowers inflammation.
   - **Examples:** Guselkumab, Risankizumab, Tildrakizumab
   - **Effect:** Significant and long-lasting improvement in skin clearing and symptoms. potent for psoriasis ranging from mild to severe.

4. **IL-12/23 Inhibitors**
   - **Mechanism:** IL-12 and IL-23 have a p40 subunit in common. By focusing on this subunit, IL-12/23 inhibitors block the signaling pathways for both IL-12 and IL-23.
   - **Examples:** Ustekinumab
   - **Effect:** Efficient in lowering inflammation and enhancing psoriatic symptoms, such as joint involvement and skin lesions. For psoriasis ranging from moderate to severe.

5. **PDE4 Inhibitors**
   - **Mechanism:** By modifying intracellular cyclic AMP levels, phosphodiesterase 4 (PDE4) inhibitors decrease the synthesis of pro-inflammatory cytokines.
   - **Examples:** Apremilast
   - **Effect:** Provides anti-inflammatory properties throughout the body, which helps individuals with moderate to severe plaque psoriasis feel better.

By focusing on certain immunological pathways implicated in the pathophysiology of psoriasis, these biologic medicines have transformed the management of the condition and provided viable alternatives for those whose responses to traditional therapy are insufficient. Because each form of biologic therapy has a distinct mechanism of action and clinical profile, treatment plans may be customized based on the severity and features of each patient's condition.[18,19,20,21]

EFFECTIVENESS

When used to treat moderate to severe psoriasis, biologic medicines have shown to be highly effective, frequently leading to notable improvements in symptoms and quality of life for many patients.

Clinical Effectiveness

1. **Psoriasis Area and Severity Index (PASI) Improvement**
   - Significant decreases in PASI scores, which gauge the intensity and scope of psoriatic lesions, are usually the result of biologic use. Responses on the PASI 75, PASI 90, and PASI 100 measure 75%, 90%, and total resolution of psoriasis symptoms, respectively.
2. **Speed of Onset**
   - After starting therapy, many biologics begin to show noticeable improvements in a matter of weeks or months. Its speedy start of action is advantageous for those who need more immediate symptom alleviation.
3. **Long-Term Maintenance**
   - Long-term effectiveness of biologics has been shown; many patients have been able to maintain response and remission with ongoing therapy. This resilience is essential for treating long-term illnesses like psoriasis.[22,23]

Specific Biologics and Efficacy

1. **TNF-alpha Inhibitors**
   - Research has demonstrated that TNF-alpha inhibitors, such as infliximab, etanercept, and adalimumab, can provide PASI 75 responses in a considerable proportion of patients, frequently between 50% and 80%.
   - Variables like illness severity, past treatment history, and unique patient features might affect response rates.

2. **IL-17 Inhibitors**
   - Clinical studies have shown that secukinumab and ixekizumab, which target IL-17A, are highly effective. About 70% to 80% of patients have received PASI 75 answers, with a sizable percentage receiving PASI 90 or greater responses.
   - Further IL-17 inhibitors, such as netakimab and bimekizumab, are also demonstrating encouraging outcomes in ongoing research.

3. **IL-23 Inhibitors**
   - Ustekinumab, which targets IL-12/23, has demonstrated effectiveness in around 70% of patients based on PASI 75 responses. The response rates to more recent IL-23-specific inhibitors, such guselkumab, risankizumab, and tildrakizumab, have been considerably greater, frequently surpassing 80% for PASI 75.
   - Patients who need long-term maintenance or who have not responded to previous therapy benefit most from these medications.[24,25]

Comparative Effectiveness

- **Head-to-Head Trials:** Several studies have directly compared various biologic therapy. The majority of the time, the results indicate similar effectiveness across various biologics; nevertheless, patient variables may cause individual responses to differ.
- **Patient Factors:** Variables like the length and severity of the disease, comorbidities, and genetics might affect efficacy. To maximize results, personalized treatment options take these characteristics into account.

Real-World Experience

- **Long-Term Data:** Studies and registries conducted in real-world settings offer important insights into the efficacy of biologic therapy in standard clinical practice. They validate the long-term advantages and safety profile seen in carefully monitored clinical studies.
- **Adherence and Persistence:** Biologics that have easy-to-follow dose regimens, such once every 12 weeks, can increase patient satisfaction and long-term efficacy.[26.27]

SAFETY PROFILE

In the treatment of psoriasis, biologic medicines have often demonstrated a positive safety profile; but, as with any drugs, there is a possible risk profile that has to be carefully considered and well monitored.

1. **Infections**: An elevated risk of infections is one of the main issues with biologics. Patients who use biologics may be more vulnerable to bacterial, viral, and fungal infections because biologics have the potential to partially suppress the immune system. There have been reports of serious illnesses, including tuberculosis (TB), thus screening for latent TB and keeping an eye out for infection symptoms are essential.
2. **Injection Site Reactions**: Some individuals may have minor injection site responses, such swelling, redness, or itching. Usually fleeting, these responses go away on their own.
3. **Hypersensitivity Reactions**: While rare, hypersensitivity responses, such as anaphylaxis, can happen soon after biologics are administered. During the first dosages, patients are closely observed in order to identify and immediately handle such responses.
4. **Malignancies**: The extended use of biologics, especially TNF-alpha inhibitors, has sparked worries about a higher risk of developing certain malignancies, such lymphomas. Though it seems minimal overall, the danger must be weighed against the advantages of therapy.
5. **Autoimmune Disorders**: Biologics may infrequently cause or worsen autoimmune conditions. To identify any indications or symptoms of recently developing autoimmune disorders, close observation is necessary.
6. **Cardiovascular Events**: There may be a cardiovascular risk linked with certain biologics, especially IL-17 inhibitors. Individuals who already have cardiovascular disease need to be properly watched.
7. **Pregnancy and Breastfeeding**: There is a paucity of safety information about the use of biologics throughout these stages of life. The possible dangers and advantages to the mother and the unborn child should be carefully considered before using biologics in these circumstances.
8. **Rare Side Effects**: Biologics may also have unusual but potentially dangerous adverse effects, such as hepatotoxicity, lupus-like syndrome, or demyelinating illnesses (such as symptoms resembling multiple sclerosis). Throughout therapy, it's critical to keep an eye out for these ailments.[28,29,30]

EMERGING THERAPIES AND FUTURE DIRECTIONS

In order to improve efficacy, safety, and patient outcomes, new therapeutic techniques and strategies for biologic therapy for psoriasis are concentrated on improving current methods and investigating novel processes. The following are some significant advancements and trends in biologic treatments for psoriasis.

1. **Next-Generation IL-17 Inhibitors**
   - **Enhanced Specificity**: More recent IL-17 inhibitors are being created, and they may have longer half-lives in addition to enhanced specificity. These include medications such as bimekizumab, which targets IL-17A and IL-17F specifically in an effort to more effectively suppress the IL-17 pathway.

2. **IL-23p19 Selective Inhibitors**
   - **Focused Targeting**: Research and development are still ongoing for biologics that target the p19 subunit of IL-23, such as risankizumab and guselkumab. These medications provide a focused method of blocking the primary cytokine responsible for maintaining inflammation in psoriasis while leaving IL-12, which is important for host defense systems, unaffected.

3. **Combination Therapies**
   - **Dual Blockade**: To achieve synergistic effects and possibly increase treatment efficaciousness, investigational studies are investigating the potential benefits of combining biologics with distinct mechanisms of action (e.g., IL-17 and IL-23 inhibitors). This is especially relevant for patients with more severe disease or inadequate response to monotherapy.

4. **Long-Acting Formulations**
   - **Extended Interval Dosing**: Research is being done to create biologics that have longer intervals between doses so that the number of injections or infusions required to achieve therapeutic effectiveness can be decreased. The goal of this strategy is to increase treatment regimen adherence and convenience.

5. **Biosimilars**
   - **Increasing Availability**: By offering more treatment options and perhaps lowering healthcare costs, biosimilars—biologic drugs that are strikingly identical to an already authorized reference product—are making biologic therapy for psoriasis more accessible.

6. **Personalized Medicine Approaches**
   - **Biomarkers and Predictive Testing**: Research is ongoing to find genetic variables and biomarkers that might forecast a patient's reaction to a particular biologic therapy. By customizing care to each patient's unique needs, this personalized medicine strategy seeks to maximize results.

7. **Immunomodulatory Strategies**
   - **Novel Targets**: Investigating other targets within the immune system, such as T cell activation regulators or cytokine signaling pathways other than IL-17 and IL-23, may lead to the development of novel biologic therapeutics with perhaps distinct modes of action.

8. **Safety Monitoring and Long-term Data**
   - **Continuous Evaluation**: In order to guarantee patient safety and therapeutic efficacy, it is still essential to continuously assess the safety profiles of biologic medicines, including uncommon side events and long-term consequences like the risk of cancer.

Psoriasis biologic therapy have generally advanced in terms of specificity, effectiveness, and patient-centered strategies. By providing tailored and efficient treatment alternatives that enhance quality of life and long-term disease management, these developments seek to satisfy the many demands of psoriasis patients, especially those with more severe illness.[31 to 35]

CONCLUSION

This thorough analysis concludes by highlighting the noteworthy developments and therapeutic advantages of biologic treatments for the treatment of psoriasis. By focusing on certain immunological pathways, biologics have completely changed the manner that treatment outcomes are achieved. This has led to tremendous improvements in patient quality of life and disease activity management. In addition, their excellent safety records—which show fewer chances of systemic side effects as compared to conventional systemic treatments—emphasize their significance as a mainstay of contemporary psoriasis treatment. Even with these developments, further research is necessary to improve treatment plans, maximize long-term results, and handle new issues including accessibility and cost-effectiveness. In general, biologic treatments are an important part of the treatment arsenal for psoriasis, providing significant disease control and better patient outcomes in clinical settings.

REFERENCES

1. Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol, 2022 Jun 10; 13: 880201.
2. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al.. Psoriasis and Comorbid Diseases: Epidemiology. *J Am Acad Dermatol*, 2017; 76(3): 377–90.
3. Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb, 2016 Jun 14; 3(1): 79-82
4. P. Patil, P. Padalkar, B. Pawar, A. Surwase and Amol Jadhav: A Review On Psoriasis: Types, Development, Mechanism And Precautions. Bull. Env.Pharmacol. Life Sci., Spl, 2023; (1): 87-92.
5. Di Meglio P, Villanova F, Nestle FO. (2014). Psoriasis. Cold Spring Harb Perspect Med, 1; 4(8): a015354
6. Branisteanu DE, Cojocaru C, Diaconu R, Porumb EA, Alexa AI, Nicolescu AC, Brihan I, Bogdanici CM, Branisteanu G, Dimitriu A, Zemba M, Anton N, Toader MP, Grechin A, Branisteanu DC. Update on the etiopathogenesis of psoriasis (Review). Exp Ther Med, 2022 Mar; 23(3): 201.
7. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun, 2015 Nov; 64: 66-73.
8. Dand N, Mahil SK, Capon F, Smith CH, Simpson MA, Barker JN. Psoriasis and Genetics. *Acta Derm Venereol*, 2020; 100(adv00030)
9. Fry L, Baker BS. Triggering psoriasis: The role of infections and medications. *Clin Dermatol*, 2007; 25: 606–615.
10. Lee HJ, Kim M. Challenges and Future Trends in the Treatment of Psoriasis. Int J Mol Sci, 2023 Aug 28; 24(17): 13313.

11. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician, 2017 Apr; 63(4): 278-285
12. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol, 2010; 62(1): 114–35.
13. Purnamawati S, Indrastuti N, Danarti R, Saefudin T. The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review. Clin Med Res, 2017 Dec; 15(3-4): 75-87.
14. Raychaudhuri SP, Raychaudhuri SK. Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases. Indian J Dermatol, 2009; 54(2): 100-9.
15. Johnston SL. Biologic therapies: what and when? J Clin Pathol. 2007 Jan; 60(1): 8-17. doi: 10.1136/jcp.2005.032300. Erratum in: J Clin Pathol, 2007 Mar; 60(3): 336.
16. Valenzuela F, Flores R. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. Clinics (Sao Paulo), 2021 Oct 1; 76: e3015.
17. Sivamani RK, Correa G, Ono Y, Bowen MP, Raychaudhuri SP, Maverakis E. Biological therapy of psoriasis. Indian J Dermatol, 2010 Apr-Jun; 55(2): 161-70.
18. Pastore S, Gubinelli E, Leoni L, Raskovic D, Korkina L. Biological drugs targeting the immune response in the therapy of psoriasis. Biologics, 2008 Dec; 2(4): 687-97.
19. Dogra A, Sachdeva S. Biologic therapy in psoriasis. Indian J Dermatol Venereol Leprol, 2006; 72: 256-265.
20. Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos C. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease. World J Gastroenterol, 2018 Sep 28; 24(36): 4093-4103.
21. Yang K, Oak ASW, Elewski BE. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. Am J Clin Dermatol, 2021 Mar; 22(2): 173-192.
22. Girolomoni G, Savage L, Gisondi P, Svensson Å, Mahé E, Augustin M, Puig L. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review. Dermatol Ther (Heidelb), 2023 Oct; 13(10): 2171-2185.
23. Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci, 2020 Mar 1; 21(5): 1690.
24. Lin, PT., Wang, SH. & Chi, CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. *Sci Rep*, 2018; **8:** 16068.
25. Xu S, Gao X, Deng J, Yang J, Pan F. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. *J Dtsch Dermatol Ges*, 2021; 19: 47–56.
26. Yun H, Xie F, Delzell E, Chen L, Yang S, Saag KG, Joseph G, Harrison D, Curtis JR. The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population. Br J Clin Pharmacol, 2015 Dec; 80(6): 1447-57.
27. Zhang H, Wen J, Alexander GC, et alComparative effectiveness of biologics and targeted therapies for psoriatic arthritisRMD Open, 2021; 7: e001399.
28. Iannone LF, Bennardo L, Palleria C, Roberti R, De Sarro C, Naturale MD, Dastoli S, Donato L, Manti A, Valenti G, D'Amico D, D'Attola S, De Francesco AE, Bosco V, Donato Di Paola E, Nisticò SP, Citraro R, Russo E, De Sarro G. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS One, 2020 Nov 3; 15(11): e0241575.
29. Lockwood SJ, Prens LM, Kimball AB. Adverse Reactions to Biologics in Psoriasis. *Curr Probl Dermatology*, 2017; 53: 1–14.
30. Lee HJ, Kim M. Challenges and Future Trends in the Treatment of Psoriasis. Int J Mol Sci, 2023 Aug 28; 24(17): 13313.
31. Ramessur R., Corbett M., Marshall D., Acencio M.L., Barbosa I.A., Dand N., Di Meglio P., Haddad S., Jensen A.H.M., Koopmann W., et al. Biomarkers of disease progression in people with psoriasis: A scoping review. *Br. J. Dermatol*, 2022; 187: 481–493.
32. Zhu B, Jing M, Yu Q, Ge X, Yuan F, Shi L. Treatments in psoriasis: from standard pharmacotherapy to nanotechnology therapy. Postepy Dermatol Alergol, 2022 Jun; 39(3): 460-471.
33. Martin A, Thatiparthi A, Liu J, Wu JJ. Interleukin-17 Inhibitor Combination Therapies for the Treatment of Psoriasis: A Systematic Review. J Clin Aesthet Dermatol, 2022 Jun; 15(6 Suppl 1): S19-S31.
34. Drakos A, Torres T, Vender R. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents. *Pharmaceutics*, 2024; 16(1): 111.
35. Strohal R, Prinz JC, Girolomoni G, Nast A. A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus. J Eur Acad Dermatol Venereol, 2015 Dec; 29(12): 2390-8.